Callaway Golf Company Announces Second Quarter 2020 Financial Results; The Company’s Business Is Recovering From COVID-19 More Quickly Than Expected

dnrt8765

CARLSBAD, Calif., Aug. 6, 2020 /PRNewswire/ — Callaway Golf Company (the “Company”) (NYSE:ELY) announced today financial results for the quarter ended June 30, 2020.

“The second quarter began as an extremely challenging operating environment in all of our global markets as we saw the height of worldwide regulatory restrictions related to COVID-19,” commented Chip Brewer, President and Chief Executive Officer of Callaway Golf Company. “In the face of these challenges, I am pleased that we were able to achieve positive non-GAAP earnings and Adjusted EBITDAS during the second quarter and am pleased with how strongly our core

Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights

dnrt8765

Press release content from PR Newswire. The AP news staff was not involved in its creation.

FREMONT, Calif., Aug. 6, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported business highlights and financial results for the second quarter ended June 30, 2020.

“Over the last quarter, we continued to make critical progress towards our goal of providing our first-in-class therapy tenapanor to adult CKD patients on dialysis with elevated serum phosphorus, a condition, despite traditional therapies,

Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights

dnrt8765
  • Interim analysis from alloSHRINK Phase 1 trial demonstrated mPFS of 3.9 months for mCRC patients with MSS disease treated with CYAD-101 following FOLFOX preconditioning; expansion cohort of alloSHRINK trial on-track to begin by fourth quarter 2020
  • Phase 1 dose-escalation trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for r/r MM on-track to initiate by year-end 2020
  • r/r AML and MDS franchise update: Initial results from CYCLE-1 trial compared to DEPLETHINK trial leads to prioritization of CYAD-02 over CYAD-01 following preconditioning chemotherapy; CYAD-01 continues to progress in THINK trial expansion segment; additional data from r/r AML and MDS programs are

Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update

dnrt8765

–ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020–

–ARIKAYCE Included in New International Treatment Guidelines for NTM Lung Disease; Positive CHMP Opinion in European Union to Advance Global Growth–

–Brensocatib Receives FDA Breakthrough Therapy Designation in Patients with Non-Cystic Fibrosis Bronchiectasis–

BRIDGEWATER, N.J., Aug. 6, 2020 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020, and provided a business update.  

“I am incredibly proud of the …